Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,477.16
(
-1.74%
)
US TECH 100
22,906.00
(
-0.20%
)
Dow Jones
45,960.11
(
-1.01%
)
Brent Oil
103.73
(
3.04%
)
Bitcoin
67,677.99
(
-1.61%
)
News Focus
News Focus
Post# of 257295
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122815
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 186024

Tuesday, 09/15/2015 4:20:01 PM

Tuesday, September 15, 2015 4:20:01 PM

Post# of 257295
PTLA reports final phase-3 data on Annexa-A* in Xarelto reversal; all primary and secondary endpoints were achieved:

http://finance.yahoo.com/news/portola-pharmaceuticals-announces-second-part-120000557.html

PTLA reported the final phase-3 data from a similar trial in Eliquis reversal in Jun 2015 (#msg-114807697).

The phase-3 program for Annexa-A is now complete, but a phase-4 outcomes study is ongoing (#msg-109888826). PTLA expects to obtain FDA approval based on the phase-3 data only, but I wouldn’t consider this a certainty.

*f/k/a andexanet alfa.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today